Angiotensin (1-7) Analog

Fat LossMas receptor agonist / researchExperimental

Also known as: AVE0991, Mas-receptor agonist, Angiotensin-(1-7) analog

Angiotensin (1-7) Analog, also called AVE0991 or Mas-receptor agonist, is a mas receptor agonist in the MasR agonist class. Activates the Mas receptor (ACE2/Ang-(1-7)/Mas axis), opposing AT1-driven vasoconstriction and fibrosis in preclinical cardiovascular models. AVE0991 is a non-peptide Mas agonist used as a research tool.

Calculate Dose

For research use only.

Key Facts

CAS
—
Molecular Weight (MW)
—
Half-life
Short; orally active analog tested in rodents
FDA status
Not Approved
Evidence level
Insufficient Evidence
Human dose established
No
Administration Route
Not established in humans
Frequency
Not established in humans
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
Mas receptor (MAS1)

Research summary

Synthetic Mas-receptor agonist related to angiotensin-(1-7) biology, studied in cardiometabolic and fibrosis models. Not FDA-approved.

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trialsNone in reviewed sources
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studies2 reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Angiotensin (1-7) Analog profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Angiotensin (1-7) Analog dosage: no established human dose

This angiotensin (1-7) analog has no established human dosage. The profile describes a Mas-receptor agonist and names AVE0991, a non-peptide mimic that has only been tested in animals, for example 3 mg/kg a day injected into the abdomen of mice. Human trials exist only for native angiotensin-(1-7), the natural peptide the analog imitates, and they are not evidence for the analog.

Insufficient Evidence

No established human dosage.

Human clinical evidence: None identified.

Preclinical research: AVE0991 activates the Mas receptor, the receptor for angiotensin-(1-7), and has been studied in rodent models of heart, blood vessel, brain and liver disease, in mg/kg or µmol/kg amounts that do not convert to a human dose. No human study of AVE0991 was found in PubMed or ClinicalTrials.gov. Native angiotensin-(1-7) has been given to people in small cancer and COVID-19 trials, but those doses belong to the natural peptide.

Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.

Dosage evidence summary for Angiotensin (1-7) Analog
Human dosing establishedNo
RouteNot established in humans
Evidence levelInsufficient Evidence
Last reviewed2026-11-07

Preclinical and analog research

Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.

Research-reported dosing for Angiotensin (1-7) Analog, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Preclinical — AVE0991 in chronic unpredictable stress in mice (2026)Preclinical · Animal studyMale mice3 mg/kg (non-human)IntraperitonealDailyLast 2 weeks of a 21-day stress protocolLower stress hormone and blood glucose, less anxiety- and depression-like behaviourThe nonpeptide angiotensin-(1-7) mimic AVE0991 attenuates neuroendocrine and behavioral responses to chronic unpredictable stress. Psychopharmacology (Berl). 2026.
Preclinical — AVE0991 in angiotensin II-induced aortic aneurysm in mice (2020)Preclinical · Animal studyApolipoprotein E knockout mice0.58 or 1.16 µmol/kg a day (non-human)Not stated in the indexed abstractDaily—Aneurysms in 48% (low dose) and 28% (high dose) versus 76% with vehicleAVE0991, a nonpeptide angiotensin-(1-7) mimic, inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E knockout mice. J Mol Med (Berl). 2020.
Native angiotensin-(1-7), not the analog — phase 1 in advanced cancer (2009)Clinical trial · Phase 1 dose-escalation trial of the parent peptide (analog evidence)Studied an analog, not Angiotensin (1-7) Analog itselfAdults with advanced solid tumours not responding to standard therapy (n=18)Escalating doses; 400 mcg/kg was the recommended phase 2 dose, and 700 mcg/kg caused dose-limiting stroke and cranial neuropathySubcutaneousOnce daily for 5 days in each 3-week cycleUntil disease progression or unacceptable toxicityOne patient had a 19% tumour reduction and three had stable disease beyond 3 monthsPhase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009.
Native angiotensin-(1-7), not the analog — phase 2 in metastatic sarcoma (2016)Clinical trial · Phase 2 trial of the parent peptide (analog evidence)Studied an analog, not Angiotensin (1-7) Analog itselfAdults with metastatic sarcoma (n not stated in the indexed abstract)20 mgSubcutaneousDaily—Well tolerated; median progression-free survival 2.7 months; the biomarker effect seen in phase 1 was not confirmedPhase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma. Sarcoma. 2016.
Native angiotensin-(1-7), not the analog — COVID-19 in intensive care (2024)Clinical trial · Seamless phase 1-2 randomised trial of the parent peptide (analog evidence)Studied an analog, not Angiotensin (1-7) Analog itselfAdults with COVID-19 pneumonia in intensive care (28 in phase 1, 79 in phase 2)5 mcg/kg a day rising to 10 mcg/kg a day after 24 hours (phase 1), or 10 mcg/kg a day (phase 2)Continuous intravenous infusionContinuousUp to 7 days or until ICU dischargeNo significant difference in oxygen-free days in phase 2; one bradycardia possibly related to infusion; stopped early for slow recruitmentAngiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial. Ann Intensive Care. 2024.

Where sources disagree

  • AVE0991 is not a peptide, while angiotensin-(1-7) is a seven-amino-acid peptide. They act on the same receptor, but doses of one are not doses of the other.
  • This profile's listed formula, C41H62N12O11, is that of native angiotensin-(1-7), while its synonyms name AVE0991. Products sold under this name may be either compound, which changes what any evidence means for them.

Reconstitution

These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.

Calculate reconstitution & dose →

Handling & administration

Timing Notes
Explored in hypertension / fibrosis research.

Sequence & molecular data

Sequence and molecular data for Angiotensin (1-7) Analog
Half-lifeShort; orally active analog tested in rodents
AppearanceWhite powder (research)
FormulationLyophilized Powder
PubChem CID9851724
FDA UNII68JR6NCI7I
ChEMBLCHEMBL4303593

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Activates the Mas receptor (ACE2/Ang-(1-7)/Mas axis), opposing AT1-driven vasoconstriction and fibrosis in preclinical cardiovascular models. AVE0991 is a non-peptide Mas agonist used as a research tool.

Origin

Synthetic Mas-receptor agonist (AVE0991 is non-peptide).

Targets

Mas receptor (MAS1)

Research statistics

88 PubMed publications · 0.0% human clinical research · 0 registered trials

Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Angiotensin (1-7) Analog is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Angiotensin (1-7) Analog
FDA statusNot Approved
AvailabilityResearch-Only
WADA (sport)Unknown / Not Listed
Library classificationResearch-Only

How FDA approval, compounding and research-only status differ

Benefits

Cardiometabolic pathway researchAnti-fibrotic models

Angiotensin (1-7) Analog side effects

Angiotensin (1-7) Analog has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.

Side Effects

  • Limited human data
  • Hypotension possible in models

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

Angiotensin (1-7) Analog: frequently asked questions

What is Angiotensin (1-7) Analog?

Synthetic Mas-receptor agonist related to angiotensin-(1-7) biology, studied in cardiometabolic and fibrosis models. Not FDA-approved.

How does Angiotensin (1-7) Analog work?

Activates the Mas receptor (ACE2/Ang-(1-7)/Mas axis), opposing AT1-driven vasoconstriction and fibrosis in preclinical cardiovascular models. AVE0991 is a non-peptide Mas agonist used as a research tool.

Is Angiotensin (1-7) Analog FDA approved?

No. Angiotensin (1-7) Analog is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What is the half-life of Angiotensin (1-7) Analog?

Reported half-life for Angiotensin (1-7) Analog is Short; orally active analog tested in rodents. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

What peptides are similar to Angiotensin (1-7) Analog?

Compounds most often compared with Angiotensin (1-7) Analog include 5-Amino-1MQ, Adipotide, AICAR and AOD-9604. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4

This Angiotensin (1-7) Analog profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Angiotensin (1-7) Analog research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →